Peripherally active CB1R inverse agonists or neutral antagonists, which are expected to show effective anti-obesity activities while circumventing the adverse central nervous system-associated effects of the first-generation brain-penetrating CB1R antagonists are, therefore, being investigated in several locations (Chorvat, 2013; Fulp et al., 2016; Knani et al., 2016; Lu et al., 2016; Iyer et al., 2017). Here, CNR1 is linked to Obesity.